A novel cause for abnormal liver function tests in pregnancy and the puerperium: non-alcoholic fatty liver disease

Background: Nowadays, generating shear waves and simulation of the liver tissue is done using point shear-wave elastographic (pSWE) techniques which uess acoustic radiation force impulse (ARFI). Objective: This study aimed to evaluate the correlation between pSWE and liver function tests (LFTs) to predict liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Materials and methods: It was a cross sectional study conducted in an Ultrasound Clinic in Suleymaniya city. The duration of the study was from 1st of November, 2018 to 30th of June, 2019 which conducted on 50 NAFLD patients. After confirming NAFLD diagnosis, the patients were referred to Ultrasound Clinic to go under pSWE test. Results: The data showed that the mean PSWE of NAFLD patient was 4.12±0.87 Kpa; and 18% of them had high PSWE (> 4.6). Elastography fibrosis score was distributed to F0 (82%), F1 (6%), F2 (8%) and F3 (4%). There was a significant association between high APRI and high Aspartate Aminotransferase/Alanine Aminotransferase(AST/ALT) ratio (p=0.04). There was also a highly significant association between elastography fibrosis score and APRI fibrosis score among NAFLD patients (p<0.001). Conclusion: This study showed that the pSWE is a valuable noninvasive diagnostic technique for predicting liver fibrosis among NAFLD patients and there is significant correlation between APRI and pSWE scores. Keywords: Non-alcoholic fatty liver disease, Point shears wave elastography, Liver fibrosis.

Download Full-text

Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph17103518 ◽

2020 ◽

Vol 17 (10) ◽

pp. 3518

Author(s):

Dariusz Narankiewicz ◽

Josefina Ruiz-Nava ◽

Veronica Buonaiuto ◽

María Isabel Ruiz-Moreno ◽

María Dolores López-Carmona ◽

...

Keyword(s):

Liver Disease ◽

Liver Function ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Liver Function Tests ◽

Mediterranean Population ◽

Alcoholic Fatty Liver ◽

Metabolic Phenotypes ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

The aim of this study was to analyze the utility of liver function tests (LFT) and fatty liver index (FLI), a surrogate marker of non-alcoholic fatty liver disease, in the categorization of metabolic phenotypes in a Mediterranean population. A cross-sectional study was performed on a random representative sample of 2233 adults assigned to a health center in Málaga, Spain. The metabolic phenotypes were determined based on body mass index (BMI) categorization and the presence or absence of two or more cardiometabolic abnormalities (high blood pressure, low high-density lipoprotein (HDL) cholesterol, hypertriglyceridemia, pre-diabetes) or type 2 diabetes. No difference was observed between metabolically healthy and metabolically abnormal phenotypes on LFT. The mean FLI of the population was 41.1 ± 28.6. FLI was significantly higher (p < 0.001) in the metabolically abnormal phenotypes in all BMI categories. The proportion of individuals with pathological FLI (≥60) was significantly higher in the metabolically abnormal overweight and obese phenotypes (p < 0.001). On a multivariate model adjusted for sex, age, and waist circumference, a significant correlation was found between pathological FLI and metabolically abnormal phenotypes in the overweight and obese BMI categories. Area under the curve (AUC) of FLI as a biomarker was 0.76, 0.74, and 0.72 for the metabolically abnormal normal-weight, overweight, and obese groups, respectively. Liver biochemistry is poorly correlated with metabolic phenotypes. Conversely, a good correlation between FLI, as a marker of non-alcoholic fatty liver disease (NAFLD), and metabolically abnormal phenotypes in all BMI ranges was found. Our study suggests that FLI may be a useful marker for characterizing metabolically abnormal phenotypes in individuals who are overweight or obese.

Download Full-text

P847 DAYTIME SLEEPINESS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IS LINKED TO INSULIN RESISTANCE, ELEVATED LIVER FUNCTION TESTS AND FIBROSIS

Journal of Hepatology ◽

10.1016/s0168-8278(14)61008-4 ◽

2014 ◽

Vol 60 (1) ◽

pp. S354

Author(s):

C. Bernsmeier ◽

D.M. Weisskopf ◽

J. Mosimann ◽

B. Campana ◽

A.C. Meyer-Gerspach ◽

...

Keyword(s):

Insulin Resistance ◽

Liver Disease ◽

Liver Function ◽

Fatty Liver ◽

Daytime Sleepiness ◽

Fatty Liver Disease ◽

Liver Function Tests ◽

Alcoholic Fatty Liver ◽

Elevated Liver Function Tests ◽

Alcoholic Fatty Liver Disease

Download Full-text

Alterations of liver function tests in diabetic obese and nonobese individuals

Biomedicine ◽

10.51248/.v41i4.681 ◽

2021 ◽

Vol 41 (4) ◽

pp. 781-786

Author(s):

Avinash S. ◽

Santhi Silambanan

Keyword(s):

Liver Disease ◽

Liver Function ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Cost Effective ◽

Liver Function Tests ◽

P Value ◽

Alcoholic Fatty Liver ◽

Nonalcoholic Fatty Liver ◽

Function Tests

Introduction and Aim: India has emerged as the diabetes capital in Southeast Asia having around 74 million with diabetes, with a prevalence of 9.8% in 18–99 years of age. In type 2 diabetes mellitus, triglycerides get deposited in liver thus altering its structure and function, which is the feature of nonalcoholic fatty liver disease. This study was undertaken to study the alterations in liver function tests in obese and nonobese diabetic individuals. Materials and Methods: The Department of Biochemistry at Sri Ramachandra Institute of Higher Education and Research was chosen to conduct the retrospective study on 200 diabetic individuals from September 2019 to February 2020. The data obtained were serum liver function tests, HbA1c, plasma glucose and lipid profile. Before the study ethics approval was obtained from the Institutional Ethics Committee for studies involving human participants. The obtained data were subjected to statistical analysis using SPSS version 16 and a P value less than 0.05 was considered statistically significant. Results: Transaminases and ALP were significantly altered in obese diabetics; were positively correlated with bilirubin. TGL was negatively correlated with AST/ALT ratio. Conclusion: Liver enzymes and bilirubin were altered in obese diabetics. Measurement of liver function biomarkers are cost effective diagnostic markers of non-alcoholic fatty liver disease.

Download Full-text

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia

BMJ Open Gastroenterology ◽

10.1136/bmjgast-2019-000368 ◽

2020 ◽

Vol 7 (1) ◽

pp. e000368 ◽

Cited By ~ 1

Author(s):

Igor V Maev ◽

Aleksey A Samsonov ◽

Liudmila K Palgova ◽

Chavdar S Pavlov ◽

Elena N Shirokova ◽

...

Keyword(s):

Liver Disease ◽

Liver Function ◽

Observational Study ◽

Fatty Liver Disease ◽

Liver Function Tests ◽

Newly Diagnosed ◽

Alcoholic Fatty Liver ◽

Function Tests ◽

Metabolic Comorbidities ◽

Alcoholic Fatty Liver Disease

ObjectiveNon-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal results of liver function tests. Earlier research showed that polyenylphosphatidylcholine (PPC) has hepatoprotective effects and thus can be used for the treatment of NAFLD and the prevention of its progression. Accordingly, the aim of this observational study was to evaluate if PPC administered as adjunctive therapy in routine clinical practice can effectively improve liver function tests of NAFLD in Russian patients with associated metabolic comorbidities.DesignA total of 2843 adult patients with newly diagnosed NAFLD, who had a least one of four comorbidities, namely, overweight/obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolaemia, and who were prescribed 1.8 g/day of PPC as an adjunctive treatment to standard care, were enrolled during 2015–2016. Laboratory data were collected at baseline and 12 and 24 weeks of the study, and included liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT)), fasting plasma glucose, and lipid profile.ResultsOverall, 2263 patients (79.6%) had at least two metabolic comorbidities associated with NAFLD, and overweight/obesity was the most common comorbidity reported in 2298 (80.8%) patients. At 24 weeks, there was a significant decrease in liver enzyme levels (all p<0.001 compared with baseline). Across the four comorbidity subgroups, there was a mean drop of ALT levels ranging from 19.7 to 22.0 U/L, AST from 16.9 to 18.4 U/L, and GGT from 17.2 to 18.7 U/L. Similar findings were reported in subgroups with either one, two, three, or four comorbidities, with a significant decrease in liver enzyme levels ranging from 18.4 to 22.4 U/L for ALT, 14.8 to 18.7 U/L for AST, and 15.5 to 19.5 U/L for GGT.ConclusionsAdjuvant treatment with PPC resulted in consistent improvements in liver enzymes in patients with newly diagnosed NAFLD and associated metabolic comorbidities.Trial registration numberNCT00063622.

Download Full-text